How can medical and safety technology manufacturers provide support during a pandemic?
Here, we look into the many ways in which medical and safety technology manufacturer Dräger has been stepping up to help its customers through the COVID-19 crisis.
Why a reformed social care system in the UK cannot wait
Fiona Carragher, Director of Research and Influencing at Alzheimer’s Society walks us through why a reformed social care system in the UK cannot wait.
From COVID-19 to the future of public health surveillance
Andrea Ammon, Director at the European Centre for Disease Prevention and Control, takes us on a journey from COVID-19 to the future of public health surveillance.
We must find other ways to keep NHS teams safe when they can’t work...
Dr Anas Nader, co-founder and CEO of Patchwork Health, discusses why we must find reliable ways to keep NHS teams safe when they can't work from home during the pandemic.
Selecting hand hygiene products in a global pandemic
Chris Wakefield, Vice President of GOJO Industries-Europe Ltd, explores how businesses can navigate the increase in cleaning products on the market and select products that will best meet their needs.
COVID-19 testing labs: Size isn’t everything
When it comes to COVID-19 testing labs, size isn’t everything, according to Alan Thornhill, UK Country Manager at Igenomix and Honorary Professor of Reproductive Genetics at the University of Kent, who spoke to Natalie Broome (MSc student, Kent).
The Moderna vaccine has a final efficiency of 94.1%
The clinical trials are over for the Moderna vaccine - the company announced their drug was 94.1% effective and then filed for Emergency Use.
Can the right technology end health inequalities?
Technology is becoming more pervasive, becoming increasingly integrated into our lives as the days pass - can it help to end health inequalities?
Medical authorities call for better HIV testing in Europe
The European Centre for Disease Control (ECDC) and the World Health Organisation (WHO) found that HIV testing in Europe is not good enough - 53% of diagnosis happens when the immune system is already failing.
AstraZeneca vaccine makes mistake in dose calculation
The Oxford and AstraZeneca vaccine trial gave an accidental half-dose to 3,000 people - but this mistake is the reason the vaccine acted as 90% efficient.
COVID-19 mutation does not make virus more infectious
Researchers at University College London have found that COVID-19 mutations do not make the virus more likely to spread, as previously feared.
More evidence on how to manage chronic pain can bring relief
Dr Ganesan Baranidharan, consultant in anaesthesia and pain medicine at the Leeds Teaching Hospitals NHS Trust, explains the power of neuromodulation for managing chronic pain and explains why comprehensive evidence is needed.
SureWash over the sink: Combining hand hygiene training & monitoring
SureWash, a hand hygiene training company, has developed a new way of combining training and monitoring of hand washing.
Public sector health procurement: Spark DPS
Helen Dempster, Founder of Karantis360, explores the benefits of Spark DPS and what future developments are required to improve the public sector health procurement journey even further.
Oxford and AstraZeneca vaccine is 70.4% effective
The UK's answer to Pfizer and Moderna, the Oxford and AstraZeneca vaccine, has proven to be exactly 70.4% effective against COVID-19.
US healthcare workers could get Pfizer vaccine in December
Today (20 November) Pfizer and BioNTech are sending their drug for approval to the FDA, meaning that the most vulnerable Americans could get the vaccine in December.
Delirium could be a sign of COVID-19 in asymptomatic older patients
Asymptomatic older patients of COVID-19 are one of the most difficult to identify - now, researchers find that delirium could be an indicator of the virus
Afro-Caribbean people with kidney problems face COVID hospitalisation
New research explores the link between ethnicity and ESKD, which finds that Afro-Caribbean patients are four times more likely to undergo COVID hospitalisation.
Oxford COVID vaccine creates strong immunisation in older people
New data from the Oxford COVID vaccine trial shows that the UK antidote is working well at Phase two, with defining percentages expected after Phase Three is complete.
US experienced spike in insomnia during first COVID lockdown
A significant increase in online searches for "insomnia" signalled to researchers that the first COVID lockdown was hard-hitting on mental health in the US.